tiprankstipranks
Aptose Biosciences’ New AML Treatment Advances
Company Announcements

Aptose Biosciences’ New AML Treatment Advances

Story Highlights

Aptose Biosciences (TSE:APS) has released an update.

Don't Miss our Black Friday Offers:

Aptose Biosciences has announced that its new triplet therapy protocol for treating newly diagnosed AML patients has been approved by the FDA to proceed. Furthermore, an abstract on the therapy’s safety and efficacy has been submitted for presentation at an upcoming ASH annual meeting. The company also addressed a Nasdaq deficiency notice regarding its share price.

For further insights into TSE:APS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAptose Biosciences Boosts Capital with $8M Offering
TipRanks Auto-Generated NewsdeskAptose Biosciences Announces $8 Million Public Offering
TheFlyAptose Biosciences to sell 40M shares at 20c in public offering
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App